Hansa Biopharma AB (publ) announced that the current chair Ulf Wiinberg has chosen to not stand for re-election.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.44 SEK | -4.91% | +9.37% | +77.25% |
05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
05-31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.25% | 313M | |
+20.86% | 46.93B | |
+37.63% | 39.08B | |
-8.10% | 38.48B | |
+29.14% | 31.01B | |
-13.75% | 26.14B | |
+10.76% | 25.88B | |
+36.09% | 12.53B | |
-7.11% | 11.36B | |
-12.53% | 10.65B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB's Current Chair Ulf Wiinberg Has Chosen to Not Stand for Re-Election